The Carlyle Group to acquire a majority stake in SeQuent Scientific for $210m.

The Carlyle Group agreed to acquire a majority stake in SeQuent Scientific, an integrated pharmaceutical company, for $210m. "SeQuent emerged as India’s leading animal healthcare company within six years, completing phase one of SeQuent’s growth journey. On behalf of the entire management team, I would like to thank Mr. Arun Kumar for his vision and support in building a global animal healthcare company. We look forward to a new phase of development, where we together with Carlyle will work to grow the company into one of the top global animal healthcare companies," Manish Gupta, SeQuent CEO.